Corbus Pharmaceuticals Holdings, Inc. (CRBP)
NASDAQ: CRBP · Real-Time Price · USD
7.40
-0.62 (-7.73%)
At close: Jun 27, 2025, 4:00 PM
7.74
+0.34 (4.59%)
After-hours: Jun 27, 2025, 7:13 PM EDT
CRBP Employees
Corbus Pharmaceuticals Holdings had 28 employees as of December 31, 2024. The number of employees increased by 9 or 47.37% compared to the previous year.
Employees
28
Change (1Y)
9
Growth (1Y)
47.37%
Revenue / Employee
n/a
Profits / Employee
-$1,796,000
Market Cap
90.55M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
CRBP News
- 3 days ago - Corbus Pharmaceuticals Announces First Patient Dosed with its Nectin-4 Targeting ADC CRB-701 in Combination with Pembrolizumab - GlobeNewsWire
- 3 days ago - Corbus Pharmaceuticals to Participate in the 3rd Annual Piper Obesity Symposium - GlobeNewsWire
- 10 days ago - Corbus Pharmaceuticals: Is Its Pipeline Really Worthless After Novo's Negative Data? - Seeking Alpha
- 5 weeks ago - Corbus Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Corbus Pharmaceuticals Names Industry Veteran Rachelle Jacques as Board Chair - GlobeNewsWire
- 3 months ago - Corbus Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Study of Next-Generation CB1 Inverse Agonist CRB-913 for the Treatment of Obesity - GlobeNewsWire
- 4 months ago - CRB-701 (SYS6002) A Next Generation Nectin-4 Targeting ADC Demonstrates Encouraging Safety and Broader Efficacy in Phase 1 Study in the US and UK Presented at ASCO-GU 2025 - GlobeNewsWire
- 4 months ago - Corbus Pharmaceuticals Announces Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at 2025 ASCO-GU - GlobeNewsWire